Download PDF
Semin Respir Crit Care Med 2008; 29(5): 542-551
DOI: 10.1055/s-0028-1085705
© Thieme Medical Publishers

Using Animal Models to Develop New Treatments for Tuberculosis

Eric Nuermberger1 , 2
  • 1Department of Medicine, Johns Hopkins University, Baltimore, Maryland
  • 2Department of International Health, Johns Hopkins University, Baltimore, Maryland
Further Information

Publication History

Publication Date:
22 September 2008 (online)

    Permissions and Reprints

ABSTRACT

Animal models have an important role in the preclinical evaluation of new antituberculosis drug candidates. Although it does not recapitulate the clinicopathological manifestations of tuberculosis in humans, the mouse remains the best characterized and most economical animal model for experimental chemotherapy. Provided care is taken to optimize the experimental conditions, the mouse has produced reliable data on the bactericidal and sterilizing activity of existing antituberculosis drugs and informed numerous clinical trials. Still, other animal models, especially the guinea pig, may have utility as confirmatory, or even alternative, models under certain circumstances. This chapter reviews some of the important considerations when selecting an animal model and presents a model for the sequential evaluation of a new compound with promising antituberculosis activity.

KEYWORDS

Tuberculosis - treatment - animal models - latent tuberculosis infection

REFERENCES

  • 1 Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA Mycobacteria, vol 2: Chemotherapy. New York; Chapman & Hall 1998: 51-97
    Google Scholar
  • 2 Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.  Bull Int Union Tuberc. 1978;  53 5-12
    PubMedGoogle Scholar
  • 3 Grosset J, Grumbach F, Rist N. Le role de la rifampicine dans la phase ultime du traitement de la tuberculose murine experimentale.  Rev Fr Mal Respir. 1978;  6 515-520
    PubMedGoogle Scholar
  • 4 Grumbach F. La duree optimale de l'antibiotherapie par l'association isoniazide + rifampicine dans la tuberculose experimentale de la souris. Etude de la phase post-therapeutique. Epreuve de la cortisone.  Rev Fr Mal Respir. 1967;  3 625-634
    PubMedGoogle Scholar
  • 5 Mitchison D A. Basic concepts in the chemotherapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA Mycobacteria, vol 2: Chemotherapy. New York; Chapman & Hall 1998: 15-50
    Google Scholar
  • 6 Warner D F, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.  Clin Microbiol Rev. 2006;  19 558-570
    CrossrefPubMedGoogle Scholar
  • 7 Balaban N Q, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch.  Science. 2004;  305 1622-1625
    CrossrefPubMedGoogle Scholar
  • 8 Medina E, North R J. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype.  Immunology. 1998;  93 270-274
    CrossrefPubMedGoogle Scholar
  • 9 Chapuis L, Ji B, Truffot-Pernot C, O'Brien R J, Raviglione M C, Grosset J H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.  Am J Respir Crit Care Med. 1994;  150 1355-1362
    CrossrefPubMedGoogle Scholar
  • 10 Lenaerts A J, Gruppo V, Brooks J V, Orme I M. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.  Antimicrob Agents Chemother. 2003;  47 783-785
    CrossrefPubMedGoogle Scholar
  • 11 Nuermberger E L, Yoshimatsu T, Tyagi S et al.. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.  Am J Respir Crit Care Med. 2004;  170 1131-1134
    CrossrefPubMedGoogle Scholar
  • 12 Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.  Antimicrob Agents Chemother. 2003;  47 3117-3122
    CrossrefPubMedGoogle Scholar
  • 13 Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.  Eur J Clin Microbiol Infect Dis. 2004;  23 243-255
    CrossrefPubMedGoogle Scholar
  • 14 Dickinson J, Guy A, Mitchison D A. Bioavailability of rifampin in experimental murine tuberculosis.  Antimicrob Agents Chemother. 1992;  36 2066-2067
    PubMedGoogle Scholar
  • 15 Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.  Antimicrob Agents Chemother. 1992;  36 548-551
    PubMedGoogle Scholar
  • 16 Orme I. Search for new drugs for treatment of tuberculosis.  Antimicrob Agents Chemother. 2001;  45 1943-1946
    PubMedGoogle Scholar
  • 17 Byrne S T, Denkin S M, Gu P, Nuermberger E, Zhang Y. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.  J Med Microbiol. 2007;  56 1047-1051
    PubMedGoogle Scholar
  • 18 Tyagi S, Nuermberger E, Yoshimatsu T et al.. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.  Antimicrob Agents Chemother. 2005;  49 2289-2293
    CrossrefPubMedGoogle Scholar
  • 19 Jayaram R, Gaonkar S, Kaur P et al.. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.  Antimicrob Agents Chemother. 2003;  47 2118-2124
    CrossrefPubMedGoogle Scholar
  • 20 Jayaram R, Shandil R K, Gaonkar S et al.. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.  Antimicrob Agents Chemother. 2004;  48 2951-2957
    CrossrefPubMedGoogle Scholar
  • 21 Benator D, Bhattacharya M, Bozeman L et al.. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.  Lancet. 2002;  360 528-534
    CrossrefPubMedGoogle Scholar
  • 22 Tam C M, Chan S L, Kam K M, Goodall R L, Mitchison D A. Rifapentine and isoniazid in the continuation phase of a 6-month regimen: final report at 5 years: prognostic value of various measures.  Int J Tuberc Lung Dis. 2002;  6 3-10
    PubMedGoogle Scholar
  • 23 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.  Lancet. 1999;  353 1843-1847
    CrossrefPubMedGoogle Scholar
  • 24 Rosenthal I M, Williams K, Tyagi S et al.. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.  Am J Respir Crit Care Med. 2006;  174 94-101
    CrossrefPubMedGoogle Scholar
  • 25 Rosenthal I M, Zhang M, Williams K N et al.. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.  PLoS Med. 2007;  4 e344
    CrossrefPubMedGoogle Scholar
  • 26 Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis.  Clin Chest Med. 1980;  1 231-241
    PubMedGoogle Scholar
  • 27 Mitchison D A. Role of individual drugs in the chemotherapy of tuberculosis.  Int J Tuberc Lung Dis. 2000;  4 796-806
    PubMedGoogle Scholar
  • 28 Burman W J. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review.  Am J Med Sci. 1997;  313 355-363
    CrossrefPubMedGoogle Scholar
  • 29 Andries K, Verhasselt P, Guillemont J et al.. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis .  Science. 2005;  307 223-227
    CrossrefPubMedGoogle Scholar
  • 30 Matsumoto M, Hashizume H, Tomishige T et al.. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.  PLoS Med. 2006;  3 e466
    CrossrefPubMedGoogle Scholar
  • 31 Nuermberger E, Rosenthal I, Tyagi S et al.. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.  Antimicrob Agents Chemother. 2006;  50 2621-2625
    CrossrefPubMedGoogle Scholar
  • 32 Nuermberger E L, Yoshimatsu T, Tyagi S et al.. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.  Am J Respir Crit Care Med. 2004;  169 421-426
    PubMedGoogle Scholar
  • 33 Kelly B P, Furney S K, Jessen M T, Orme I M. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis .  Antimicrob Agents Chemother. 1996;  40 2809-2812
    PubMedGoogle Scholar
  • 34 Canetti G. The Tubercle Bacillus in the Pulmonary Lesions of Man. New York; Springer 1955
    Google Scholar
  • 35 Opie E J, Aronson J D. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions.  Arch Pathol Lab Med. 1927;  4 1-21
    PubMedGoogle Scholar
  • 36 McCune R M, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique.  J Exp Med. 1956;  104 737-802
    CrossrefPubMedGoogle Scholar
  • 37 Lecoeur H F, Truffot-Pernot C, Grosset J H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.  Am Rev Respir Dis. 1989;  140 1189-1193
    CrossrefPubMedGoogle Scholar
  • 38 Nuermberger E L, Yoshimatsu T, Tyagi S, Bishai W R, Grosset J H. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.  Infect Immun. 2004;  72 1065-1071
    CrossrefPubMedGoogle Scholar
  • 39 Quigley M A, Mwinga A, Hosp M et al.. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.  AIDS. 2001;  15 215-222
    CrossrefPubMedGoogle Scholar
  • 40 Mwinga A, Hosp M, Godfrey-Faussett P et al.. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.  AIDS. 1998;  12 2447-2457
    CrossrefPubMedGoogle Scholar
  • 41 Halsey N A, Coberly J S, Desormeaux J et al.. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.  Lancet. 1998;  351 786-792
    CrossrefPubMedGoogle Scholar
  • 42 Gordin F, Chaisson R E, Matts J P et al.. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.  JAMA. 2000;  283 1445-1450
    CrossrefPubMedGoogle Scholar
  • 43 Ji B, Truffot-Pernot C, Lacroix C et al.. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.  Am Rev Respir Dis. 1993;  148 1541-1546
    CrossrefPubMedGoogle Scholar
  • 44 Nuermberger E, Tyagi S, Williams K N, Rosenthal I, Bishai W R, Grosset J H. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.  Am J Respir Crit Care Med. 2005;  172 1452-1456
    CrossrefPubMedGoogle Scholar
  • 45 Schechter M, Zajdenverg R, Falco G et al.. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.  Am J Respir Crit Care Med. 2006;  173 922-926
    CrossrefPubMedGoogle Scholar
  • 46 Dhillon J, Dickinson J M, Sole K, Mitchison D A. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.  Antimicrob Agents Chemother. 1996;  40 552-555
    PubMedGoogle Scholar
  • 47 Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.  Antimicrob Agents Chemother. 1993;  37 407-413
    PubMedGoogle Scholar
  • 48 Karlson A G. Therapeutic effect of ethambutol on experimental tuberculosis of guinea pigs.  Am Rev Respir Dis. 1961;  84 902-904
    PubMedGoogle Scholar
  • 49 Karlson A G, Feldman W H. Isoniazid in experimental tuberculosis of guinea pigs infected with tubercle bacilli resistant to streptomycin and to para-aminosalicylic acid.  Am Rev Tuberc. 1952;  66 477-485
    PubMedGoogle Scholar
  • 50 Bjerkedal T, Palmer C E. Effect of isoniazid prophylaxis in experimental tuberculosis in guinea pigs: action of isoniazid in vivo.  Am J Hyg. 1962;  76 89-123
    PubMedGoogle Scholar
  • 51 Dickinson J M, Mitchison D A. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol.  Tubercle. 1976;  57 251-258
    PubMedGoogle Scholar
  • 52 Helke K L, Mankowski J L, Manabe Y C. Animal models of cavitation in pulmonary tuberculosis.  Tuberculosis (Edinb). 2006;  86 337-348
    CrossrefPubMedGoogle Scholar
  • 53 Elwood R L, Wilson S, Blanco J C et al.. The American cotton rat: a novel model for pulmonary tuberculosis.  Tuberculosis (Edinb). 2007;  87 145-154
    CrossrefPubMedGoogle Scholar
  • 54 Karakousis P C, Yoshimatsu T, Lamichhane G et al.. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice.  J Exp Med. 2004;  200 647-657
    CrossrefPubMedGoogle Scholar

Eric NuermbergerM.D. 

1550 Orleans St., Baltimore

MD 21231

Email: enuermb@jhmi.edu